| 000 | 01623 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518094817.0 | ||
| 264 | 0 | _c20210113 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a2169-141X | ||
| 024 | 7 |
_a10.1080/21691401.2020.1748885 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYousefi, Amir-Mohammad | |
| 245 | 0 | 0 |
_aZnO/CNT@Fe _h[electronic resource] |
| 260 |
_bArtificial cells, nanomedicine, and biotechnology _cDec 2020 |
||
| 300 |
_a735-745 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aFerrosoferric Oxide _xchemistry |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImatinib Mesylate _xpharmacology |
| 650 | 0 | 4 | _aK562 Cells |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aNanocomposites _xchemistry |
| 650 | 0 | 4 |
_aNanoparticles _xchemistry |
| 650 | 0 | 4 |
_aNanotubes, Carbon _xchemistry |
| 650 | 0 | 4 |
_aReactive Oxygen Species _xmetabolism |
| 650 | 0 | 4 |
_aSirtuin 1 _xgenetics |
| 650 | 0 | 4 |
_aZinc Oxide _xchemistry |
| 700 | 1 | _aSafaroghli-Azar, Ava | |
| 700 | 1 | _aFakhroueian, Zahra | |
| 700 | 1 | _aBashash, Davood | |
| 773 | 0 |
_tArtificial cells, nanomedicine, and biotechnology _gvol. 48 _gno. 1 _gp. 735-745 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/21691401.2020.1748885 _zAvailable from publisher's website |
| 999 |
_c30840134 _d30840134 |
||